HomeCompareSBBP vs EPRT

SBBP vs EPRT: Dividend Comparison 2026

SBBP yields 100.00% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBBP wins by $3.83M in total portfolio value
10 years
SBBP
SBBP
● Live price
100.00%
Share price
$2.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.90M
Annual income
$1,312,946.05
Full SBBP calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — SBBP vs EPRT

📍 SBBP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSBBPEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SBBP + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SBBP pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SBBP
Annual income on $10K today (after 15% tax)
$8,500.00/yr
After 10yr DRIP, annual income (after tax)
$1,116,004.14/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, SBBP beats the other by $1,105,089.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SBBP + EPRT for your $10,000?

SBBP: 50%EPRT: 50%
100% EPRT50/50100% SBBP
Portfolio after 10yr
$1.98M
Annual income
$662,893.38/yr
Blended yield
33.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

SBBP
Analyst Ratings
9
Buy
2
Hold
Consensus: Buy
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SBBP buys
0
EPRT buys
0
No recent congressional trades found for SBBP or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSBBPEPRT
Forward yield100.00%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$3.90M$63.4K
Annual income after 10y$1,312,946.05$12,840.73
Total dividends collected$3.48M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SBBP vs EPRT ($10,000, DRIP)

YearSBBP PortfolioSBBP Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$20,700$10,000.00$11,205$505.18+$9.5KSBBP
2$41,495$19,345.79$12,672$682.46+$28.8KSBBP
3$80,643$36,243.16$14,490$930.48+$66.2KSBBP
4$152,116$65,828.38$16,786$1,282.69+$135.3KSBBP
5$278,813$116,048.53$19,753$1,791.56+$259.1KSBBP
6$497,119$198,789.52$23,677$2,541.64+$473.4KSBBP
7$863,169$331,251.38$29,008$3,672.99+$834.2KSBBP
8$1,461,129$537,538.09$36,463$5,425.08+$1.42MSBBP
9$2,413,798$850,390.15$47,238$8,221.57+$2.37MSBBP
10$3,895,710$1,312,946.05$63,385$12,840.73+$3.83MSBBP

SBBP vs EPRT: Complete Analysis 2026

SBBPStock

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.

Full SBBP Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this SBBP vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SBBP vs SCHDSBBP vs JEPISBBP vs OSBBP vs KOSBBP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.